Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study

References

• Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. Aaps J. 13(2):143–151.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. 2015. Statistics Notes: Bootstrap resampling methods. BMJ. 350:h2622.
   PubMed Web of Science ®Google Scholar
• Cheng X, Zhao Y, Gu H, Zhao L, Zang Y, Wang X, Wu R. 2020. The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia. Int J Immunopathol Pharmacol. 34:2058738420934936.
   Web of Science ®Google Scholar
• Djebli N, Rousseau A, Hoizey G, et al. 2006. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet. 45(11):1135–1148.
   PubMed Web of Science ®Google Scholar
• Ferrarese A, Cattelan A, Cillo U, Gringeri E, Russo FP, Germani G, Gambato M, Burra P, Senzolo M. 2020. Invasive fungal infection before and after liver transplantation. World J Gastroenterol. 26(47):7485–7496.
   PubMed Web of Science ®Google Scholar
• Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. 1997. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 61(4):416–428.
   PubMed Web of Science ®Google Scholar
• Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman A-H, Brüggemann RJM. 2017. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 19(5):e12751.
   Web of Science ®Google Scholar
• Husain S, Camargo JF. 2019. Invasive aspergillosis in solid-organ transplant recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 33(9):e13544.
   PubMed Web of Science ®Google Scholar
• Jiao Z, Shi XJ, Li ZD, Zhong MK. 2009. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br J Clin Pharmacol. 68(1):47–60.
   PubMed Web of Science ®Google Scholar
• MacDonald A, Scarola J, Burke JT, Zimmerman JJ. 2000. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 22(Suppl B):B101–121.
   Google Scholar
• Mahalati K, Kahan BD. 2001. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 40(8):573–585.
   PubMed Web of Science ®Google Scholar
• Marks DI, Liu Q, Slavin M. 2017. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. Expert Rev anti Infect Ther. 15(5):493–502.
   PubMed Web of Science ®Google Scholar
• Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, Antin JH. 2006. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 12(5):552–559.
   PubMed Web of Science ®Google Scholar
• Masters JC, Shah MM, Feist AA. 2014. Drug interaction between sirolimus and ranolazine in a kidney transplant patient. Case Rep Transplant. 2014:548243.
   PubMedGoogle Scholar
• Mathis AS, Shah NK, Friedman GS. 2004. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc. 36(9):2708–2709.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M, Vinks AA. 2017. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. Br J Clin Pharmacol. 83(5):1097–1107.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Guchelaar HJ, de Fijter JW. 2015. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 20(10):1243–1249.
   PubMed Web of Science ®Google Scholar
• Owens KH, Murphy PGM, Medlicott NJ, Kennedy J, Zacharias M, Curran N, Sreebhavan S, Thompson-Fawcett M, Reith DM. 2014. Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. J Pharmacokinet Pharmacodyn. 41(3):211–221.
   PubMed Web of Science ®Google Scholar
• Sadaba B, Campanero MA, Quetglas EG, Azanza JR. 2004. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc. 36(10):3226–3228.
   PubMed Web of Science ®Google Scholar
• Scott JR, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA. 2013. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. Ther Drug Monit. 35(3):332–337.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. 2003. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 35(3 Suppl):7S–14S.
   PubMed Web of Science ®Google Scholar
• Shao S, Hu L, Han Z, Hou K, Fang H, Zhang G, Feng Y, Huang L. 2020. The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: a meta-analysis. Transl Androl Urol. 9(2):673–683.
   PubMed Web of Science ®Google Scholar
• Surowiec D, DePestel DD, Carver PL. 2008. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy. 28(6):719–729.
   PubMed Web of Science ®Google Scholar
• Tamashiro EY, Felipe CR, Genvigir FDV, Rodrigues AC, Campos AB, Hirata RDC, Tedesco-Silva H, Medina-Pestana JO. 2017. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther. 32(2):89–95.
   PubMedGoogle Scholar
• Trotter JF. 2003. Sirolimus in liver transplantation. Transplant Proc. 35(3 Suppl):193S–200S.
   PubMedGoogle Scholar
• Wang D, Chen X, Li Z. 2019. Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: a retrospective study. Oncol Lett. 18(3):2412–2419.
   PubMed Web of Science ®Google Scholar
• Wu K, Cohen EEW, House LK, Ramírez J, Zhang W, Ratain MJ, Bies RR. 2012. Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer. CPT Pharmacometrics Syst Pharmacol. 1(12):e17.
   PubMedGoogle Scholar
• Zahir H, Keogh AM, Akhlaghi F. 2006. Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. Ther Drug Monit. 28(5):614–622.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dai Y, Liu Z, Zhang M, Li C, Chen D, Song H. 2017. Effect of CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of sirolimus in healthy Chinese volunteers. Ther Drug Monit. 39(4):406–411.
   PubMed Web of Science ®Google Scholar
• Zimmerman JJ, Kahan BD. 1997. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 37(5):405–415.
   PubMed Web of Science ®Google Scholar